Another Interaction of the FcR System with IVIG

James B. Bussel

doi:10.1055/s-0037-1613329

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2002; 88(06): 890-891
DOI: 10.1055/s-0037-1613329

Commentary

Schattauer GmbH

Another Interaction of the FcR System with IVIG

James B. Bussel

¹Weill Medical College of Cornell University, Division of Pediatrics, New York, NY, USA

References
1 Imbach P, Barandun S, d’Apuzzo V, Baumgartner C. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 01 8232: 1228-31.
2 Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic throbocytopenic purpura by high-dose intravenous gammaglobulin. N Eng J Med 1982; 306 (21) 1254-8.
3 Bussel JB, Kimberly RP, Inman RD, Cunningham-Rundles C, Smithwick E, Schulman I, Cheung N, O’Malley J, Barandun S, Hilgartner MW. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983; 62 (02) 480-6.
4 Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000; Jul; 37 (03) 261-6.
5 Clarkson SB, Bussel JB, Kimberly RP, Valinsky J, Nachman RL, Unkeless JC. Treatment of refractory immune thrombocytopenia purpura with an anti-Fc receptor antibody. N Eng J Med 1986; 314 (19) 1236-9.
6 Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet 1983; 02 8343: 193-5.
7 Scaradavou A, Woo B, Woloski BMR, Cunningham-Rundles S, Ettinger L, Aledort LM, Bussel JB. Intravenous Anti-D Treatment of Immune Thrombocytopenic Purpura: Experience in 272 Patients. Blood 1997; 89: 2689-700.
8 Bonnet DM, Fridman WH, Carosella E, Philippe N, Reinert P, Vilmer E, Kaplan C, Teillaud JL, Griscelli C. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342 8877: 945-9.
9 Terjanian T, Sher H, Vemuri R, Windsor K, Nicolay U, Vessey A, Deo Y, Curnow R. A proof-of-concept phase 2 study of monoclonal antibody MDX-33 in adult subjects with chronic stable ITP. Abstract. Blood 2000; 96 (11) 251a.
10 Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291 5503: 484-6.
11 Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. NEJM 1999; 340 (03) 227-8.
12 Brambell FWR, Hemmings WA, Morris IG. A theoretical model of y-Globulin catabolism. Nature 1964; 203: 1352-5.
13 Waldmann TA, Strober W. Metabolism of Immunoglobulins. Prog Allergy 1969; 13: 1-110.
14 Junghans RP. IgG biosynthesis: No “immunoregulatory feedback”. Blood 1997; 90 (10) 3815-8.
15 Ghetie V, Ward ES. FcRn: the MHC class I-regulated receptor that is more than an IgG transporter. Review Immunology Today 1997; 18 (12) 592-8.
16 Tsubakio T, Kurata Y, Katagiri S. et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gammaglobulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exper Immunol 1983; 53: 697.
17 Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies. Proc Natl Acad Sci 1987; 84 (03) 828-31.
18 Berchtold P, Dale GL, Tani P, Mcmillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74 (07) 2309-17.
19 Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002; 100: 2087-93.